Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inactivation of Cancer Mutations Utilizing CRISPR/Cas9.

Journal of the National Cancer Institute - 1 Jan 2017

Gebler Christina, Lohoff Tim, Paszkowski-Rogacz Maciej, Mircetic Jovan, Chakraborty Debojyoti, Camgoz Aylin, Hamann Martin V, Theis Mirko, Thiede Christian, Buchholz Frank

Abstract excerpt

Although whole-genome sequencing has uncovered a large number of mutations that drive tumorigenesis, functional ratification for most mutations remains sparse. Here, we present an approach to test functional relevance of tumor mutations employing CRISPR/Cas9. Combining comprehensive sgRNA design and an efficient reporter assay to nominate efficient and selective sgRNAs, we establish a pipeline to dissect roles of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Cleavage
Share to Endonucleases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Nucleophosmin

Share to Carcinoma

Share to Clustered Regularly Interspaced Short Palindromic Repeats

Share to Colonic Neoplasms

Share to CRISPR-Associated Protein 9

Share to RNA, Guide, CRISPR-Cas Systems

Source

Open in PubMed Open full text

Identifiers

PMID: 27576906
DOI: 10.1093/jnci/djw183
PMCID: PMC6284257

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inactivation of Cancer Mutations Utilizing CRISPR/Cas9.PMID 27576906Read ↗

Using CRISPR-Cas9 to Dissect Cancer Mutations in Cell Lines.Semantic proximity Read ↗

Precision Oncology in the CRISPR Era: Applications and Future Horizons in Cancer TherapySemantic proximity Read ↗

Precision Oncology in the CRISPR Era: Applications and Future Horizons in Cancer TherapySemantic proximity Read ↗

Current Status of CRISPR/Cas9 Application in Clinical Cancer Research: Opportunities and ChallengesSemantic proximity Read ↗

CRISPR/Cas9 technology in tumor research and drug development application progress and future prospectsSemantic proximity Read ↗

Engineering CRISPR/Cas9 therapeutics for cancer precision medicineSemantic proximity Read ↗

CRISPR/Cas9 for Cancer Therapy: Hopes and ChallengesSemantic proximity Read ↗

Genome Editing Approaches with CRISPR/Cas9 for Cancer Treatment: Critical Appraisal of Preclinical and Clinical Utility, Challenges, and Future ResearchSemantic proximity Read ↗

The application of CRISPR/Cas9–based genome-wide screening to disease researchSemantic proximity Read ↗

Application of CRISPR/Cas9 Technology in Cancer Treatment: A Future Direction.Semantic proximity Read ↗

CRISPR-Cas9 as a Potential Cancer Therapy Agent: An UpdateSemantic proximity Read ↗

Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.